FindTrial
Sign In

A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine followed by an open follow-up evaluation to assess consistency

A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine followed by an open follow-up evaluation to assess consistency

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-000244-90-IT
Enrollment
160
Registered
2005-03-17
Start date
2005-03-08
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of migraine MedDRA version: 6.1 Level: PT Classification code 10027599

Interventions

Trade Name: ALMOGRAN*3 CPR RIV. 12,5 MG Product Name: NA Product Code: NA Pharmaceutical Form: Coated tablet INN or Proposed INN: Almotriptan Concentration unit: mg milligram(s) Concentration type: eq

Sponsors

ALMIRALL PRODESFARMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026